BioSpace News Archive

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, provided commentary on its current banking relationship with Silicon Valley Bank.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Omeros Corporation, in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.

Intelligent Bio Solutions Inc. announced the closing of its previously announced underwritten public offering of 654,990 shares of common stock and warrants to purchase up to 196,497 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants.

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced its financial results for the three and 12 months ended December 31, 2022, and provided a clinical and business update.

New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer.

Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year 2022 financial results and discuss recent business highlights.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Kiromic BioPharma, Inc. announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time , March 10, 2023.

Crinetics Pharmaceuticals, Inc. announced that on March 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 250,300 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc.